Advertisement

The role of depression in the relationship between cognitive decline and quality of life among breast cancer patients

  • Jin-Hee Park
  • Yong Sik Jung
  • Young-Mi Jung
  • Sun Hyoung BaeEmail author
Original Article
  • 74 Downloads

Abstract

Purpose

Cancer patients who underwent chemotherapy experience cognitive decline, which, in turn, negatively impacts quality of life (QoL). Depression is considered a psychological factor that is negatively associated with the QoL of cancer patients. However, the relationships among cognitive functioning, depression, and QoL in breast cancer patients are under-researched in the literature. The aim of this cross-sectional study was to identify the role of depression in the relationship between cognitive functioning and QoL among breast cancer patients.

Methods

One hundred thirty breast cancer patients who underwent primary treatment participated. Participants completed the Functional Assessment of Cancer Therapy-Cognitive Function version 3, the Montreal Cognitive Assessment, the Beck Depression Inventory-II, and the Functional Assessment of Cancer Therapy-Breast Scale. The data were analyzed using multiple regression according to Baron and Kenny’s strategies and the Sobel test.

Results

Subjective and objective cognitive functioning and depression were statistically significant predictors of QoL in breast cancer patients. Depression played a partial mediating role in the relationship between objective cognitive functioning and QoL and between subjective cognitive functioning and QoL. Additionally, the Sobel test demonstrated that depression had a significant partial mediating effect between subjective cognitive functioning and QoL (Z = 4.91, p < 0.001) and between objective cognitive functioning and QoL (Z = 2.62, p = 0.009).

Conclusions

The findings indicated that depression could influence the association between cognitive functioning and QoL in breast cancer patients. Healthcare providers should develop an intervention focused on decreasing depression to evaluate the effectiveness of improving quality of life for breast cancer patients with cognitive dysfunction.

Keywords

Cognition Cognitive dysfunction Quality of life Depression Breast neoplasms 

Notes

Acknowledgements

We would like to thank the study participants for their time and dedication to this study. We also thank the staff at the Breast Cancer Center, Ajou University Medical Center, Suwon, Republic of Korea, for their cooperation.

Funding

This study was supported by a grant from the Ajou University, College of Nursing.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Park EH, Min SY, Kim Z, Yoon CS, Jung KW, Nam SJ, Oh SJ, Lee S, Park BW, Lim W, Hur MH, Korean Breast Cancer Society (2017) Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer 20(1):1–11.  https://doi.org/10.4048/jbc.2017.20.1.1 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer survivorship care guideline. J Clin Oncol 34(6):611–635.  https://doi.org/10.1200/JCO.2015.64.3809 CrossRefGoogle Scholar
  3. 3.
    Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934.  https://doi.org/10.1016/j.ctrv.2012.05.002 CrossRefPubMedGoogle Scholar
  4. 4.
    Von AD, Habermann B, Carpenter JS et al (2013) Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17(2):236–241.  https://doi.org/10.1016/j.ejon.2012.06.002 CrossRefGoogle Scholar
  5. 5.
    Falleti MG, Sanfilippo A, Maruff P, Weih LA, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59(1):60–70.  https://doi.org/10.1016/j.bandc.2005.05.001 CrossRefPubMedGoogle Scholar
  6. 6.
    Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26(1):102–113.  https://doi.org/10.3109/09540261.2013.864260 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E (2006) A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20(1):76–89.  https://doi.org/10.1080/138540491005875 CrossRefPubMedGoogle Scholar
  8. 8.
    Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514.  https://doi.org/10.1200/JCO.2016.68.5826 CrossRefPubMedGoogle Scholar
  9. 9.
    Baxter MF, Dulworth AN, Smith TM (2011) Identification of mild cognitive impairments in cancer survivors. Occup Ther Health Care 25(1):26–37.  https://doi.org/10.3109/07380577.2010.533251 CrossRefPubMedGoogle Scholar
  10. 10.
    Koppelmans V, Breteler MM, Boogerd W et al (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30(10):1080–1086.  https://doi.org/10.1200/jco.2011.37.0189 CrossRefPubMedGoogle Scholar
  11. 11.
    Myers JS, Wick JA, Klemp J (2015) Potential factors associated with perceived cognitive impairment in breast cancer survivors. Support Care Cancer 23(11):3219–3228.  https://doi.org/10.1007/s00520-015-2708-7 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Reich M, Lesur A, Perdrizet-Chevallier C (2008) Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 110(1):9–17.  https://doi.org/10.1007/s10549-007-9706-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez-Fernandez S, Fernandez-Rodriguez C, Mota-Alonso MJ et al (2017) Emotional state and psychological flexibility in breast cancer survivors. Eur J Oncol Nurs 30:75–83.  https://doi.org/10.1016/j.ejon.2017.08.006 CrossRefPubMedGoogle Scholar
  14. 14.
    Henneghan A, Stuifbergen A, Becker H, Kesler S, King E (2017) Modifiable correlates of perceived cognitive function in breast cancer survivors up to 10 years after chemotherapy completion. J Cancer Surviv 12(2):224–233.  https://doi.org/10.1007/s11764-017-0661-9 CrossRefPubMedGoogle Scholar
  15. 15.
    Miura K, Ando S, Imai T (2016) The association of cognitive fatigue with menopause, depressive symptoms, and quality of life in ambulatory breast cancer patients. Breast Cancer 23(3):407–414.  https://doi.org/10.1007/s12282-014-0578-3 CrossRefPubMedGoogle Scholar
  16. 16.
    Pendergrass JC, Targum SD, Harrison JE (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci 15(1–2):36–44.  https://doi.org/10.1097/ncc.0000000000000578 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Biglia N, Bounous VE, Malabaila A et al (2012) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care 21(4):485–492.  https://doi.org/10.1111/j.1365-2354.2011.01320.x CrossRefGoogle Scholar
  18. 18.
    Oh PJ, Kim JH (2016) Chemotherapy-related cognitive impairment and quality of life in people with colon cancer: the mediating effect of psychological distress. J Korean Acad Nurs 46(1):19–28.  https://doi.org/10.4040/jkan.2016.46.1.19 CrossRefPubMedGoogle Scholar
  19. 19.
    Williams AM, Lindholm J, Siddiqui F, Ghanem TA, Chang SS (2017) Clinical assessment of cognitive function in patients with head and neck cancer: prevalence and correlates. Otolaryngol Head Neck Surg 157(5):808–815.  https://doi.org/10.1177/0194599817709235 CrossRefPubMedGoogle Scholar
  20. 20.
    Akel R, El Darsa H, Anouti B et al (2017) Anxiety, depression and quality of life in breast cancer patients in the Levant. Asian Pac J Cancer Prev 18(10):2809–2816PubMedPubMedCentralGoogle Scholar
  21. 21.
    Yeo W, Mo FK, Pang E et al (2018) Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. Cancer Manag Res 10:383–389.  https://doi.org/10.2147/CMAR.S149983 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lee JY, Lee DW, Cho SJ et al (2008) Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal cognitive assessment. J Geriatr Psychiatry Neurol 21(2):104–110.  https://doi.org/10.1177/0891988708316855 CrossRefPubMedGoogle Scholar
  23. 23.
    Wagner LI, Sweet J, Butt Z, Lai JS, Cella D (2009) Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy–cognitive function instrument. J Support Oncol 7:W32–W39Google Scholar
  24. 24.
    Nasreddine ZS, Phillips NA, Bédirian V et al (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Beck AT, Steer RA, Brown GK (1996) Manual for the Beck depression inventory–II, 2nd edn. Psychological Corporation, San AntonioGoogle Scholar
  26. 26.
    Beck AT, Steer RA, Ball R, Ranieri WF (1996) Comparison of Beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67(3):588–597.  https://doi.org/10.1207/s15327752jpa6703_13 CrossRefPubMedGoogle Scholar
  27. 27.
    Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974–986.  https://doi.org/10.1200/jco.1997.15.3.974 CrossRefPubMedGoogle Scholar
  28. 28.
    Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51(6):1173–1182.  https://doi.org/10.1037/0022-3514.51.6.1173 CrossRefPubMedGoogle Scholar
  29. 29.
    Preacher KJ, Leonardelli GJ (2008) Calculation for the Sobel test: An interactive calculation tool for mediation tests. IOP Publishing PhysicsWeb. http://quantpsy.org/sobel/sobel.htm. Accessed 20 May 2018
  30. 30.
    Andreotti C, Root JC, Ahles TA, McEwen BS, Compas BE (2015) Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline. Psychooncology 24(6):617–623.  https://doi.org/10.1002/pon.3683 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of Nursing· Research Institute of Nursing ScienceAjou UniversitySuwonRepublic of Korea
  2. 2.Department of Surgery, School of MedicineAjou UniversitySuwonRepublic of Korea
  3. 3.Department of Nursing, School of MedicineCheongju UniversityCheongjuRepublic of Korea

Personalised recommendations